Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARVN Arvinas	$6.79 +3.0%	$7.51	$5.90 ▼ $29.61	$483.45M	2.22	2.16 million shs	2.40 million shs
NKTX Nkarta	$1.96 -2.5%	$1.91	$1.31 ▼ $6.63	$142.62M	0.72	552,717 shs	364,557 shs
TYRA Tyra Biosciences	$10.60 +5.0%	$10.30	$6.42 ▼ $29.60	$536.21M	1.08	202,030 shs	132,008 shs
VALN Valneva	$9.40 +10.6%	$6.57	$3.62 ▼ $9.40	$723.30M	1.77	74,593 shs	119,388 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARVN Arvinas	+4.77%	-12.48%	-15.40%	+4.77%	-73.58%
NKTX Nkarta	+1.52%	-5.19%	+9.84%	+3.61%	-59.23%
TYRA Tyra Biosciences	-3.35%	-5.16%	-1.56%	+1.20%	-49.70%
VALN Valneva	-6.70%	+13.33%	+40.03%	+33.23%	+23.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARVN Arvinas	3.6503 of 5 stars	4.3	2.0	2.8	2.5	1.3
NKTX Nkarta	2.0375 of 5 stars	3.6	0.0	3.1	1.7	0.6
TYRA Tyra Biosciences	1.8765 of 5 stars	3.5	0.0	2.4	3.3	0.0
VALN Valneva	2.8277 of 5 stars	3.5	5.0	3.0	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARVN Arvinas	2.55	Moderate Buy	$19.76	191.06% Upside
NKTX Nkarta	3.13	Buy	$14.33	631.29% Upside
TYRA Tyra Biosciences	3.00	Buy	$30.83	190.88% Upside
VALN Valneva	3.00	Buy	$15.50	64.89% Upside

Current Analyst Ratings Breakdown

Latest NKTX, TYRA, ARVN, and VALN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	ARVN Arvinas	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $18.00
8/7/2025	ARVN Arvinas	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$19.00 ➝ $16.00
8/7/2025	ARVN Arvinas	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
7/1/2025	TYRA Tyra Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/10/2025	NKTX Nkarta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00
6/2/2025	ARVN Arvinas	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$24.00
6/2/2025	ARVN Arvinas	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$10.00 ➝ $9.00
6/1/2025	ARVN Arvinas	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/21/2025	TYRA Tyra Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$33.00
5/15/2025	ARVN Arvinas	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $21.00
5/15/2025	NKTX Nkarta	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARVN Arvinas	$263.40M	1.89	N/A	N/A	$8.30 per share	0.82
NKTX Nkarta	N/A	N/A	N/A	N/A	$5.78 per share	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	$6.78 per share	N/A
VALN Valneva	$183.52M	4.36	$0.11 per share	86.99	$2.41 per share	3.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARVN Arvinas	-$198.90M	-$1.01	N/A	N/A	N/A	-19.47%	-12.01%	-6.97%	10/29/2025 (Estimated)
NKTX Nkarta	-$108.79M	-$1.51	N/A	N/A	N/A	N/A	-26.64%	-21.62%	8/12/2025 (Estimated)
TYRA Tyra Biosciences	-$86.48M	-$1.63	N/A	N/A	N/A	N/A	-26.90%	-25.54%	8/13/2025 (Estimated)
VALN Valneva	-$13.25M	-$1.19	N/A	N/A	N/A	-43.08%	-43.05%	-16.23%	8/12/2025 (Estimated)

Latest NKTX, TYRA, ARVN, and VALN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	TYRA Tyra Biosciences	-$0.53	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	NKTX Nkarta	-$0.37	-$0.31	+$0.06	-$0.31	N/A	N/A
8/12/2025	Q2 2025	VALN Valneva	-$0.27	-$0.16	+$0.11	-$0.16	$46.28 million	N/A
8/6/2025	Q2 2025	ARVN Arvinas	-$0.87	-$0.84	+$0.03	-$0.84	$34.42 million	$22.40 million
5/14/2025	Q1 2025	NKTX Nkarta	-$0.44	-$0.43	+$0.01	-$0.43	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	N/A
VALN Valneva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARVN Arvinas	N/A	5.64	5.64
NKTX Nkarta	N/A	14.48	14.48
TYRA Tyra Biosciences	N/A	22.78	22.78
VALN Valneva	0.92	2.70	2.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARVN Arvinas	95.19%
NKTX Nkarta	80.54%
TYRA Tyra Biosciences	84.14%
VALN Valneva	11.39%

Insider Ownership

Company	Insider Ownership
ARVN Arvinas	4.73%
NKTX Nkarta	8.40%
TYRA Tyra Biosciences	15.20%
VALN Valneva	14.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARVN Arvinas	420	73.42 million	69.95 million	Optionable
NKTX Nkarta	140	70.96 million	65.00 million	Optionable
TYRA Tyra Biosciences	20	53.09 million	45.02 million	Optionable
VALN Valneva	700	85.09 million	72.41 million	Not Optionable

NKTX, TYRA, ARVN, and VALN Headlines

Recent News About These Companies

Valneva (NASDAQ:VALN) Sees Strong Trading Volume - Time to Buy?

August 12 at 3:43 PM | marketbeat.com

Valneva Shares Gain After Results, Outlook

August 12 at 4:48 AM | marketwatch.com

Valneva (NASDAQ:VALN) Trading Down 6.7% - Here's What Happened

August 12 at 2:58 AM | marketbeat.com

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates

August 12 at 2:00 AM | globenewswire.com

Valneva SE (VALN) Q2 2025: Everything You Need To Know Ahead Of Earnings

August 11 at 6:46 PM | finance.yahoo.com

Valneva (VALN) Expected to Announce Quarterly Earnings on Tuesday

August 11 at 2:49 AM | americanbankingnews.com

Valneva (NASDAQ:VALN) Hits New 12-Month High - Time to Buy?

August 10 at 3:09 AM | americanbankingnews.com

Valneva (NASDAQ:VALN) Hits New 12-Month High - Here's Why

August 9 at 10:20 AM | marketbeat.com

FDA removes Ixchiq partial pause but tightens vaccine’s use

August 8, 2025 | finance.yahoo.com

FDA lifts pause on Valneva’s Ixchiq Chikungunya vaccine

August 8, 2025 | thepharmaletter.comT

FDA tightens label of Valneva's chikungunya vaccine, lifts pause in older adults

August 8, 2025 | fiercepharma.comF

FDA Lifts Valneva’s Chikungunya Vaccine Use Restriction in Older Adults

August 8, 2025 | empr.comE

FDA lifts pause on Valneva's chikungunya vaccine in elderly

August 8, 2025 | msn.com

Valneva Updates Safety Label of Chikungunya Virus Vaccine

August 8, 2025 | managedhealthcareexecutive.comM

FDA lifts pause on Valneva’s chikungunya shot, but adds new limits

August 8, 2025 | yahoo.com

Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information

August 7, 2025 | globenewswire.com

Valneva (VALN) Projected to Post Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

VALNEVA Declaration of shares and voting rights: July 31, 2025

August 6, 2025 | finance.yahoo.com

Valneva (NASDAQ:VALN) Sees Large Volume Increase - Here's Why

July 29, 2025 | marketbeat.com

AGC Biologics’ Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva’s Tetravalent Shigella Vaccine Candidate

July 29, 2025 | finance.yahoo.com

Valneva (NASDAQ:VALN) Shares Gap Up - Still a Buy?

July 25, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTX, TYRA, ARVN, and VALN Company Descriptions

Arvinas NASDAQ:ARVN

$6.79 +0.20 (+3.03%)

Closing price 04:00 PM Eastern

Extended Trading

$6.82 +0.03 (+0.50%)

As of 07:50 PM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Nkarta NASDAQ:NKTX

$1.96 -0.05 (-2.49%)

Closing price 04:00 PM Eastern

Extended Trading

$1.97 +0.01 (+0.56%)

As of 07:58 PM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Tyra Biosciences NASDAQ:TYRA

$10.60 +0.50 (+4.95%)

Closing price 04:00 PM Eastern

Extended Trading

$10.60 0.00 (-0.05%)

As of 07:48 PM Eastern

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Valneva NASDAQ:VALN

$9.40 +0.90 (+10.59%)

Closing price 04:00 PM Eastern

Extended Trading

$8.89 -0.51 (-5.43%)

As of 07:23 PM Eastern

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time